We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+37.81%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.66B
AUM Growth
+$539M
Cap. Flow
+$598M
Cap. Flow %
12.83%
Top 10 Hldgs %
41.2%
Holding
160
New
26
Increased
26
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$372M
2
KRON
Kronos Bio
KRON
+$41.3M
3
SQZ
SQZ Biotechnologies Company
SQZ
+$41M
4
Z icon
Zillow
Z
+$38.7M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$37.2M

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$71.8M
2
BABA icon
Alibaba
BABA
+$62.5M
3
MRNA icon
Moderna
MRNA
+$25.3M
4
STNE icon
StoneCo
STNE
+$21.2M
5
SRRK icon
Scholar Rock
SRRK
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 78.81%
2 Consumer Discretionary 9.12%
3 Miscellaneous 6.2%
4 Technology 2.01%
5 Communication Services 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYPH
101
Cypherpunk Technologies Inc
CYPH
$232M
$6.75M 0.14%
300,000
+17,470
+6% +$333K
DYN icon
102
Dyne Therapeutics
DYN
$3.35B
$6.3M 0.14%
300,000
-70,000
-19% -$1.38M
OVID icon
103
Ovid Therapeutics
OVID
$525M
$5.78M 0.12%
2,500,000
– –
CYCN
104
DELISTED
Cyclerion Therapeutics
CYCN
$5.56M 0.12%
90,879
– –
MRNA icon
105
Moderna
MRNA
$57.6B
$5.22M 0.11%
50,000
-250,000
-83% -$25.3M
ACIU icon
106
AC Immune
ACIU
$263M
$5.17M 0.11%
1,000,000
– –
CFRX
107
DELISTED
ContraFect Corporation
CFRX
$5.05M 0.11%
+12,500
New +$5.41M
PRQR icon
108
ProQR Therapeutics
PRQR
$255M
$5.02M 0.11%
1,196,218
– –
KNTE
109
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.97M 0.11%
+125,000
New +$5.02M
MCRB icon
110
Seres Therapeutics
MCRB
$47.3M
$4.9M 0.11%
10,000
-5,000
-33% -$2.93M
KLDO
111
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$4.55M 0.1%
500,500
– –
AXLA
112
DELISTED
Axcella Health Inc. Common Stock
AXLA
$3.7M 0.08%
28,500
– –
KA
113
DELISTED
Kineta, Inc. Common Stock
KA
$3.7M 0.08%
+31,056
New +$4.72M
MRNS
114
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.66M 0.08%
+300,000
New +$4.18M
RNAM
115
DELISTED
Avidity Biosciences
RNAM
$3.64M 0.08%
142,500
– –
ORIC icon
116
Oric Pharmaceuticals
ORIC
$1.27B
$3.38M 0.07%
100,000
-42,500
-30% -$1.22M
ADCT icon
117
ADC Therapeutics
ADCT
$133M
$3.04M 0.07%
95,000
– –
KDNY
118
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.86M 0.06%
180,500
– –
PTGX icon
119
Protagonist Therapeutics
PTGX
$9.29B
$2.68M 0.06%
133,000
– –
LITS
120
Lite Strategy Inc
LITS
$36.1M
$2.01M 0.04%
38,000
– –
XLE icon
121
CALL
State Street Energy Select Sector SPDR ETF
XLE
$43.3B
$1.9M 0.04%
100,000
– –
ACGN
122
DELISTED
Aceragen Inc
ACGN
$1.83M 0.04%
+29,441
New +$1.69M
ACET icon
123
Adicet Bio
ACET
$76.2M
$1.82M 0.04%
8,083
– –
CHMA
124
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.65M 0.04%
380,000
– –
ORTX
125
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.52M 0.03%
35,150
– –
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2020 Portfolio in Review

As of Q4 2020, Artal Group held 160 positions worth $4.66B, up 13% from $4.12B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Artal Group deployed $598M of net new capital in Q4 2020, opening 26 new positions and adding to 26 existing holdings. Its largest new stake was Seer Inc: 5,840,911 shares worth $328M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 58% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BioNTech, an estimated $71.8M trimmed.

  • Artal Group's largest Q4 2020 buy was Seer Inc: 5,840,911 shares worth $328M.
  • Artal Group added most to Zillow in Q4 2020, an estimated $38.7M increase.
  • Artal Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $71.8M.
  • Artal Group fully exited StoneCo in Q4 2020, selling an estimated $21.2M.
  • Artal Group's ten largest holdings make up 41% of its $4.66B portfolio in Q4 2020.
  • Artal Group opened 26 new positions and closed 30 in Q4 2020.
  • Artal Group's portfolio value rose 13% quarter-over-quarter to $4.66B.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.